Italo Poggesi

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Multiple Sclerosis

Top Venues

Clinical pharmacology and therapeutics

Clinical pharmacokinetics

British journal of clinical pharmacology

Expert opinion on drug metabolism & toxicology

This page only lists publications with an associated author ORCID identifier.

Publications

Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics 113 (3) (2023)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan Jose Perez Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Ponesimod Effect on Heart Rate in Patients With Multiple Sclerosis. Clinical pharmacology and therapeutics (2022)
Veronica Di Paolo, Francesco Maria Ferrari, Italo Poggesi, Luigi Quintieri
Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction. Clinical pharmacokinetics 61 (9) (2022)
Belén Valenzuela, Italo Poggesi, Nicolas Luyckx, Andrea Vaclavkova, Juan José Pérez-Ruixo
Pharmacokinetic-Pharmacodynamic Modeling of the Effect of Ponesimod on Heart Rate in Patients with Multiple Sclerosis. Clinical pharmacology and therapeutics (2022)
Per Olsson Gisleskog, Belén Valenzuela, Tatiana Scherz, Michel Burcklen, Juan Jose Perez Ruixo, Italo Poggesi
An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis. Clinical pharmacokinetics 60 (9) (2021)
Veronica Di Paolo, Francesco Maria Ferrari, Italo Poggesi, Luigi Quintieri
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. Expert opinion on drug metabolism & toxicology 17 (11) (2021)
Roberta Bartolucci, Anne-Gaëlle Dosne, Dénes Csonka, Juan José Pérez-Ruixo, Paolo Magni, Italo Poggesi
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension. Clinical pharmacokinetics 60 (12) (2021)
Belén Valenzuela, Juan Jose Perez Ruixo, Quentin Leirens, Sivi Ouwerkerk-Mahadevan, Italo Poggesi
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis. Clinical pharmacokinetics 60 (9) (2021)
Lene Nygaard Axelsen, Italo Poggesi, Freya Rasschaert, Juan Jose Perez Ruixo, Shirin Bruderer
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. British journal of clinical pharmacology 87 (1) (2020)